UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000018370
Receipt No. R000021269
Scientific Title Clinical studies about diabetes and the neutrophilic elastase
Date of disclosure of the study information 2015/08/18
Last modified on 2016/09/06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical studies about diabetes and the neutrophilic elastase
Acronym Clinical studies about diabetes and the neutrophilic elastase
Scientific Title Clinical studies about diabetes and the neutrophilic elastase
Scientific Title:Acronym Clinical studies about diabetes and the neutrophilic elastase
Region
Japan

Condition
Condition type II diabetes mellitus
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 1.In the case of postcibal sudden elevation of glycemia, is a neutrophil activated?
2.Does the activation of this neutrophil change by taking diabetes remedy?
3.Is it different from a healthy person in this activation in patients with diabetes?
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Serum neutrophilic elastase concentrations
Key secondary outcomes Blood glucose level
Gene expression (three hours before a meal after meal) of the peripheral blood leukocyte fraction
inflammatory cytokine (IL-1b, TNFa) adhesion factor (CD11b, CD11c)
Pro-metabolism factor (IRS-1)

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria Healthy adult criteria for selection of Japanese people
(1) Age at agreement acquisition is a person younger than 60 years 20 years old or older
(2) The person that BMI (weight (kg) / [height (m) X height (m)]) at agreement acquisition is less than 25.0 more than 18.5
(3) The person whom a researcher judged to be eligible as subjects of this study
(4) Criteria for selection of patients with person Japanese type II diabetes mellitus that has the ability of the agreement, and is available for the acquisition of the document agreement from the person
(1) The patients who give a diet or a diet, exercise therapy in the instructions contents which are more constant than before more than study initiation eight weeks
(2) The patients whom we are treated with miglitol (50 mg of once or 75 mg 3 times a day) from before more than study initiation eight weeks and do not change within eight weeks
(3) The patients more than 6.5% with HbA1c at agreement acquisition less than 8.5%
(4) Age at agreement acquisition is the patient younger than 75 years 20 years old or older
(5) The patients who have the ability of the agreement, and are available for the acquisition of the document agreement from the person
Key exclusion criteria Healthy adult exclusion criteria of Japanese people
(1) Person with the clinical history
(2) The person who suffers trauma, and is treated
(3) Person with the medical history that judged that a researcher had an influence on the evaluation of the safety of subjects and the study
(4) Drug dependence, a person with the alcohol dependence or person with the history
(5) A person with sensitivity to drug or person with the history
(6) A person with the food allergy or person with the history
(7) The daily persons who smokes an average of ten or more
(8) Excessive common custom drinker
(9) Person with positive at least one among examinations of HIV antigen, antibody, HBs antigen, HCV antibody and syphilis
(10) In addition, the person who judged that an investigator or a subinvestigator was inadequate.

Exclusion criteria of patients with Japanese type II diabetes mellitus
(1) Patients with type I diabetes mellitus
(2) The patients who are judged to need treatment with insulin preparation
(3) The patients with the serious hepatic disorder
(4) The patients with serious renal disease
(5) The patients who blood pressure management is insufficient, and need a change of the pharmacotherapy immediately
(6) The patients with the serious heart disorder or the patients who caused myocardial infarction, an anginal attack within 24 weeks before study start
(7) The patients who had a stroke attack within 24 weeks before study start
(8) The patients with serious impaired pulmonary function
(9) The patients with the serious pancreatic disease
(10) The patients with the malignant tumor
(11) Severe infection, before and after surgery, the patients with the serious trauma
(12) The patients with severe diabetic complications (neuropathy, retinopathy, nephropathy)
(13) Severe ketosis, diabetic coma or the former comatose patients
(14) The endocrine disease that treatment is inadequate for by hormone replacement therapy
(15) The patients with severe anemia
(16)-(26)
Target sample size 45

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takeshi Osonoi
Organization Nakakinen clinic
Division name Director
Zip code
Address 745-5, Nakadai, Naka, Ibaraki
TEL 029-353-2800
Email t-osonoi@kensei-kai.com

Public contact
Name of contact person
1st name
Middle name
Last name Kensuke Ofuchi
Organization Nakakinen clinic
Division name Clinical Laboratory
Zip code
Address 745-5, Nakadai, Naka, Ibaraki
TEL 029-353-2800
Homepage URL
Email k-ofuchi@kensei-kai.com

Sponsor
Institute Nakakinen clinic
Institute
Department

Funding Source
Organization SANWA KAGAKU KENKYUSHO CO.,LTD
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Faculty of life Environmental Sciences,University of Yamanashi
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 08 Month 18 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2015 Year 06 Month 22 Day
Date of IRB
Anticipated trial start date
2015 Year 08 Month 01 Day
Last follow-up date
2016 Year 03 Month 31 Day
Date of closure to data entry
2016 Year 04 Month 30 Day
Date trial data considered complete
2016 Year 05 Month 31 Day
Date analysis concluded
2016 Year 06 Month 30 Day

Other
Other related information Prospective study.
Case-control study.
We Intend for all the members in an outpatient and the healthy adults who met criteria for selection.
We measure serum neutrophils elastase concentrations, an inflammatory marker, an adhesion factor, blood glucose level

Management information
Registered date
2015 Year 07 Month 21 Day
Last modified on
2016 Year 09 Month 06 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021269

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.